Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial

TRX-E-002-1 Induces c-Jun–Dependent Apoptosis in Ovarian Cancer Stem Cells and Prevents Recurrence In Vivo

“…Current standard of care consists of surgical debulking and adjuvant chemotherapy with platinum and taxane to which more than 80% of patients respond. Unfortunately, the majority of these patients eventually exhibit relapse (3), and upon disease recurrence, the value of the standard of care is limited by the presentation of carcinomatosis and chemoresistance. As such, the majority of patients with recurrent ovarian cancer eventually succumb to the disease.…”

Cancer of the ovary, fallopian tube, and peritoneum

“…The Japanese GOG (JGOG) reported the findings of the latter regimen and showed improved progression-free survival and overall survival [63]. This regimen is being compared with standard every 3 weeks intravenous and intraperitoneal regimens in several clinical trials.…”

Neoadjuvant, adjuvant and long-term intravenous/intraperitoneal chemotherapy, hyperthermic intraperitoneal chemotherapy, early postoperative intraperitoneal chemotherapy for ovarian cancer

“…The investigators concluded that NACT followed by IDS provides equal survival compared to PDS. To date, improved survival has been demonstrated in large phase III studies, proposing IP/IV chemotherapy, 27,34 dose-dense paclitaxel 35 and the addition of bevacizumab for patients with inoperable or suboptimally cytoreduced disease. 36 At some institutions, clinicians have replaced the 3-week administration of paclitaxel with the "dosedense" weekly approach, because of the superior survival demonstrated in JGOG 3016.…”

“…36 At some institutions, clinicians have replaced the 3-week administration of paclitaxel with the "dosedense" weekly approach, because of the superior survival demonstrated in JGOG 3016. 35 …”

“…Analysis revealed no difference in survival for any of the combinations. [33][34][35][36] At many institutions, patients do not receive IP/IV chemotherapy after NACT+ICS, and at present data is limited, except of two studies: i) a phase II Southwest Oncology Group Study, that studied the use of IP/IV chemotherapy after NACT+ICS in stage III/IV ovarian cancer patients, of whom optimal cytoreduction was thought to be unlikely on imaging. Only 26 patients of the 58 received NACT, ICS and postoperative IP/IV chemotherapy.…”